ClinicalTrials.gg
CompletedNCT03909529Updated May 1, 2023Results posted

Drug-drug Interaction (DDI) Study of Spironolactone (Perpetrator) and Digoxin (Substrate Drug)

A Phase 1 interventional study of Digoxin 250 MCG Oral Tablet and Spironolactone 25 mg/ 5 mL S/F Suspension in Drug Drug Interaction, sponsored by CMP Development, LLC. Completed at 1 site in India. Open to participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-01.

Sponsored by CMP Development, LLC · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
All
01

Study summary

An open label, balanced, randomized, single-dose, two-treatment, two-sequence, two-period, crossover oral drug-drug interaction study of spironolactone (perpetrator) and Digoxin (substrate drug) in healthy adult human subjects under fasting condition.

Read the detailed description

Drug interaction studies between spironolactone and digoxin, particularly studies in which digoxin was administered intravenously (Waldorf, S 1978; Fenster, P.E. 1984), indicate that spironolactone may decrease the renal clearance of digoxin by 18-25%, and increase the (area under curve) AUC of digoxin by 35-44%. Although the radioimmunoassay used in the study may be confounded, these results suggest that inhibition of P-gp in the renal proximal tubules may be possible. To account for possible renal P-gp inhibition, subjects in the test group will be pretreated with spironolactone for about 5 days to allow accumulation of some of the metabolites which have a long half-life (e.g., canrenone \~33 hours) and continue to be treated with spironolactone while digoxin is renally eliminated from the body. Based on this assessment, the FDA suggested study design is Treatment A: Single dose of digoxin alone. Treatment B: Digoxin + Spironolactone; Day 1- 9: Spironolactone single dose; Day 6: Digoxin single oral dose.

Also, digoxin has a long half-life of 1.5-2 days, and the Pharmacokinetic (PK) sampling scheme of up to 72 hours may not be enough to characterize the elimination kinetics of digoxin. Hence, the plasma concentrations of digoxin up to 96 hours (4 days) postdose is considered This will allow you to detect possible differences in the clearance of digoxin mediated by an interaction with P-gp in the renal proximal tubules.

The study also involves collecting urine samples and measuring renal clearance (CLR) and unchanged drug excreted in urine (fe) for digoxin.

02

Conditions studied

  • Drug Drug Interaction
03

In context

Lead sponsor

CMP Development, LLC is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy human subjects aged between 20 and 35 years (including both).
  • Subjects with a between 18.5 - 24.9 Kg/m2 (including both) but body weight not less than 60 Kgs.
  • Subjects who were screened at least 48 hours prior to check-in
  • Subjects with normal health as determined by personal medical history, clinical examination, and laboratory examinations including serological tests during the screening
  • Subjects with normal 2D echo
  • Subjects having normal 12-lead (ECG) or ECG with no clinical significant abnormalities as determined by Investigator.
  • Subjects having normal chest X-Ray (P/A view) or chest X-ray with no abnormalities as determined by investigator.
  • Subjects able to communicate effectively.
  • Subjects willing to give written and adhere to all the requirements of this protocol.
  • Additional inclusion criteria for female subjects, Female of practicing an acceptable method of for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence: or for at least 1 year, or Surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed on the subject).

Exclusion criteria

Exclusion Criteria:

  • Subjects having or to study drug or related group of drugs.
  • History or presence of any medical condition or disease according to the opinion of the physician.
  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
  • Subject having / corrected QT interval (QTc) >450 milliseconds
  • History or presence of significant alcoholism or drug abuse in the past one year.
  • History or presence of significant smoking (more than 10 cigarettes /day or consumption of tobacco products).
  • Subjects who fail to abstain from consuming any alcoholic products from 48.00 hours prior to check-in to till check-out / last sample of the study.
  • Subjects who fail to abstain from any xanthine-containing food and/or beverages (like chocolate, tea, coffee, cola drinks), cigarettes and tobacco containing products and grapefruit and/or it's juice from 48.00 hours prior to check-in to till check-out / last sample of the study.
  • Subjects who fail to refrain from pan or pan masala, gutkha, masala (containing beetle nut and tobacco) for 48.00 hours prior to check-in to till check-out/last sample of the study.
  • Difficulty with donating blood.
  • Systolic blood pressure less than 110 mm Hg or more than 140 mm Hg.
  • Diastolic blood pressure less than 70 mm Hg or more than 90 mm Hg.
  • Pulse rate less than 60 beats/minute or more than 100 beats/minute.
  • Use of any prescribed medication during last two weeks or over-the- counter (OTC) medicinal products/ herbal products during the last one week prior to check-in.
  • Major illness during 90 days before check-in.
  • Participation in a drug research study within past 90 days of check-in.
  • Donation of blood (i.e. one unit or 350 mL) in the past 90 days before check-in.
  • History of unusual diet consumption in the past 3 weeks before check-in.
  • Additional exclusion criteria for female subjects, Volunteer demonstrating a positive pregnancy test. Volunteers who are pregnant, currently breast-feeding or who are likely to become pregnant during the study.

Volunteers who have used implanted or injected hormonal anytime during the 6 months prior to study or used hormonal contraceptives within 14 days before dosing.

-

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    LANOXIN® (Digoxin) USP 250 mcg (substrate drug) {Treatment A}

    14 Subjects first administered with LANOXIN® (digoxin) USP 250 mcg (Substrate drug) on Day 6 of in house, after overnight fasting of at least 10.00 hours. After washout period of 28 days, these 14 subjects were administered with Spironolactone Oral Suspension 100 mg (perpetrator, Carospir® Oral Suspension 20 mL of 25 mg / 5 mL) from day 1 to day 5 and on day 6 the after overnight fasting of at least 10.00 hours, subject was administered with LANOXIN® (digoxin) USP 250 mcg (substrate drug) + Spironolactone Oral Suspension 100 mg (perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL). From day 7 to day 9 the subjects were administered with Spironolactone Oral Suspension 100 mg (perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL).

    Drug: Digoxin 250 MCG Oral Tablet

  • Experimental
    LANOXIN® (Digoxin) USP 250mcg and Carospir® Oral Suspension 20mL of 25 mg/5mL-Treatment B

    14 Subjects first administered with Spironolactone Oral Suspension 100 mg (perpetrator, Carospir® Oral Suspension 20 mL of 25 mg / 5 mL) from day 1 to day 5 and on day 6 the after overnight fasting of at least 10.00 hours, subject was administered with LANOXIN® (digoxin) USP 250 mcg (substrate drug) + Spironolactone Oral Suspension 100 mg (perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL). From day 7 to day 9 the subjects were administered with Spironolactone Oral Suspension 100 mg (perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL). After washout period of 28 days these 14 Subjects administered with LANOXIN® (digoxin) USP 250 mcg (Substrate drug) on Day 6 of in house, after overnight fasting of at least 10.00 hours

    Drug: Spironolactone 25 mg/ 5 mL S/F Suspension

Interventions

  • The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension

    Also known as: Spironolactone Oral Suspension 20 mL of 25 mg/mL

  • DrugSpironolactone 25 mg/ 5 mL S/F Suspension

    Drug page: Spironolactone

    The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension

    Also known as: DDI Spironolactone oral suspension interaction with digoxin

06

What researchers measure

Primary outcomes

  1. Dogoxin Plasma Data for Cmax

    Primary Pharmacokinetic parameter The following pharmacokinetic parameters for Digoxin were obtained using non-compartmental method Cmax, AUC0-96, and tmax using plasma data, Renal clearance (CLR) /Percent Recovered, Unchanged drug excreted in urine (fe)/Amount Recovered using urine data.

    Time frame: 4 days

  2. Digoxin Plasma Data for AUC0-96

    Area under the plasma concentration versus time curve from time 0 to the 96 hour time point concentration.

    Time frame: 4 days

Secondary outcomes

  1. Digoxin Plasma Data for Tmax

    If the maximum value occurs at more than one time point, Tmax is defined as the first time point with this value.

    Time frame: 4 days

  2. ECG Measurement Will be Performed to Evaluate Any Changes in the QT Interval

    ECG will be performed at 1.00 and 3.00 hours post dose in each period on Day 6 and at check-out of each period of the study

    Time frame: 4 days

Other outcomes

  1. Renal Clearance (CLR)/Percent Recovered

    Summary Statistics for Untransformed Urine PK Parameters of digoxin Per Treatment-Renal clearance (CLR)/Percent Recovered

    Time frame: 04 Days

  2. Unchanged Drug Excreted in Urine (fe)/ Amount Recovered

    Summary of Urine Pharmacokinetic parameters for digoxin -unchanged drug excreted in urine (fe)/ Amount Recovered

    Time frame: 04 Days

07

Results

Posted May 1, 2023

Participant flow

Open Label, Balanced, Randomized DDI
Participant flow — Open Label, Balanced, Randomized DDI
MilestoneLANOXIN First, Then CarospirFirst Carospir, Then LANOXIN
Started1414
Completed1414
Not completed00
Open Label, Balanced, Randomized DDI
Participant flow — Open Label, Balanced, Randomized DDI
MilestoneLANOXIN First, Then CarospirFirst Carospir, Then LANOXIN
Started1414
Completed1414
Not completed00

Outcome measures

PrimaryDogoxin Plasma Data for Cmax

Primary Pharmacokinetic parameter The following pharmacokinetic parameters for Digoxin were obtained using non-compartmental method Cmax, AUC0-96, and tmax using plasma data, Renal clearance (CLR) /Percent Recovered, Unchanged drug excreted in urine (fe)/Amount Recovered using urine data.

Time frame:
4 days
Reported as:
Mean · pg/mL
Dogoxin Plasma Data for Cmax
pg/mLDrug-Drug Interaction Study
Treatment A1530.188 ± 502.810
Treatment B2432.908 ± 870.562
PrimaryDigoxin Plasma Data for AUC0-96

Area under the plasma concentration versus time curve from time 0 to the 96 hour time point concentration.

Time frame:
4 days
Reported as:
Mean · pg.hr/mL
Digoxin Plasma Data for AUC0-96
pg.hr/mLDrug-Drug Interaction Study
Treatment A13715.974 ± 2669.003
Treatment B16551.500 ± 4108.500
SecondaryDigoxin Plasma Data for Tmax

If the maximum value occurs at more than one time point, Tmax is defined as the first time point with this value.

Time frame:
4 days
Reported as:
Mean · hr
Digoxin Plasma Data for Tmax
hrDrug-Drug Interaction Study
Treatment A0.744 ± 0.195
Treatment B0.901 ± 0.569
SecondaryECG Measurement Will be Performed to Evaluate Any Changes in the QT Interval

ECG will be performed at 1.00 and 3.00 hours post dose in each period on Day 6 and at check-out of each period of the study

Time frame:
4 days

Results for this outcome have not been posted.

Other pre-specifiedRenal Clearance (CLR)/Percent Recovered

Summary Statistics for Untransformed Urine PK Parameters of digoxin Per Treatment-Renal clearance (CLR)/Percent Recovered

Time frame:
04 Days
Reported as:
Mean · % recovered
Renal Clearance (CLR)/Percent Recovered
% recoveredDrug-Drug Interaction Study
Treatment A54.687 ± 29.158
Treatment B53.378 ± 21.256
Other pre-specifiedUnchanged Drug Excreted in Urine (fe)/ Amount Recovered

Summary of Urine Pharmacokinetic parameters for digoxin -unchanged drug excreted in urine (fe)/ Amount Recovered

Time frame:
04 Days
Reported as:
Mean · nanograms
Unchanged Drug Excreted in Urine (fe)/ Amount Recovered
nanogramsDrug-Drug Interaction Study
Treatment A136717.72 ± 72895.492
Treatment B133446.07 ± 53141.044

Adverse events

Collected over 9 days for period 18 Days for 2 periods. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment-A- Single Dose of Digoxin (LANOXIN)0/28 (0%)0/28 (0%)0/28 (0%)
Treatment-B-Digoxin (LANOXIN) + Spiranolactone (Carospir)0/28 (0%)0/28 (0%)0/28 (0%)

Baseline characteristics

On Day 6 of each period, after overnight fasting for at least 10.00 hours the subjects were dosed either with the Treatment (A) \[LANOXIN® (digoxin) USP 250 mcg (substrate drug)\] or Treatment (B) \[LANOXIN® (digoxin) USP 250 mcg (substrate drug) + Spironolactone Oral Suspension 100 mg (Perpetrator; Carospir® Oral Suspension 20 mL of 25 mg / 5 mL)\] as per the randomization scheme.

Age, Categorical
Age, Categorical(Participants)Drug-Drug Interaction Study
<=18 years0
Between 18 and 65 years28
>=65 years0
Age, Continuous
Age, Continuous(Years)Drug-Drug Interaction Study
Mean29 (23 to 33)
Sex: Female, Male
Sex: Female, Male(Participants)Drug-Drug Interaction Study
Female0
Male28
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Drug-Drug Interaction Study
Region of Enrollment
Region of Enrollment(participants)Drug-Drug Interaction Study
India28
08

Study locations

1 site
  • ClinSync Clinical Research Pvt. Ltd.
    Hyderabad,, Telangana 501505, India
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Apr 2019, 1 month.

Results were first posted in May 2023, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2019
First posted
Apr 10, 2019
StartActual
Mar 10, 2019
Primary completionActual
Apr 19, 2019
CompletionActual
Apr 30, 2019
Results first posted
May 1, 2023
Last update
May 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03909529
Lead sponsor
CMP Development, LLC
Responsible party
Sponsor
First posted
Apr 10, 2019
Start date
Mar 10, 2019
Primary completion
Apr 19, 2019
Completion
Apr 30, 2019
Results posted
May 1, 2023
Last update
May 1, 2023

Study contacts

Roopali K Somani, MD
principal investigator · Employee

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Digoxin · Spironolactone

Start the discussion